| RESEARCH ARTICLE |
|
| Year : 2022 | Volume
: 11
| Issue : 1 | Page : 62 |
|
|
Evaluation of growth hormone deficiency in children with cystic fibrosis
Mohsen Reisi1, Niloufar Sharif Ahmadian2, Mahin Hashemipour3, Neda Mostofizadeh3, Majid Keivanfar1, Elham Hashemi4
1 Department of Pediatrics, Faculty of Medicine, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Pediatrics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Correspondence Address:
Dr. Elham Hashemi
Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/abr.abr_285_20
|
|
|
Background: Due to chronic respiratory and gastrointestinal problems, growth failure is a common issue in patients with cystic fibrosis (CF). The present study aimed to investigate the prevalence of growth hormone deficiency (GHD) in CF children with stable gastrointestinal and respiratory conditions. Materials and Methods: In this study, the growth indicators of all 4–16-year-old children referred to two CF clinics were monitored over 3 years. Children without severe gastrointestinal or pulmonary symptoms with weight <3% percentile or whose height increase were two standard deviations below their expected height growth over 6 months were selected for the growth hormone (GH) stimulation test by clonidine and L-dopa test. Some of the children without CF, who were also referred for height growth disorders and matched the CF group, were considered the control group. They underwent the GH stimulation test, and the results were compared. Results: From 150 patients with CF, growth failure was observed in 24 patients with stable gastrointestinal and respiratory conditions; in 10 of them, the GH stimulation test was deficient. The prevalence of GHD was 6.6% in CF patients. In the control group of 30 children without CF, but with growth failure, the GH was deficient in nine cases, implying no significant difference with the case group (P = 0.37). Conclusion: In our study, the prevalence of GHD was 6.6% in CF patients, whereas the prevalence GHD in the normal population of childhood is <1%. Therefore, further studies should be designed to investigate the cause of GHD in CF patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
